On October 2, 2024, the U.S. Food and Drug Administration (FDA) determined the shortage of the tirzepatide injection, a glucagon-like peptide 1 (GLP-1) medication, has been “resolved”. The tirzepatide ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback